Resverlogix Financial Statements From 2010 to 2025
| RVXCF Stock | USD 0.03 0.01 25.00% |
Check Resverlogix Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Resverlogix Corp's main balance sheet or income statement drivers, such as , as well as many indicators such as . Resverlogix financial statements analysis is a perfect complement when working with Resverlogix Corp Valuation or Volatility modules.
Resverlogix |
Resverlogix Corp Company Return On Asset Analysis
Resverlogix Corp's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Resverlogix Corp Return On Asset | -0.96 |
Most of Resverlogix Corp's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Resverlogix Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Resverlogix Corp has a Return On Asset of -0.9632. This is 88.99% lower than that of the Biotechnology sector and 95.92% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Resverlogix Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Resverlogix Corp's current stock value. Our valuation model uses many indicators to compare Resverlogix Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Resverlogix Corp competition to find correlations between indicators driving Resverlogix Corp's intrinsic value. More Info.Resverlogix Corp is currently regarded as top stock in return on asset category among its peers. It also is currently regarded number one company in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Resverlogix Corp's earnings, one of the primary drivers of an investment's value.About Resverlogix Corp Financial Statements
Resverlogix Corp stakeholders use historical fundamental indicators, such as Resverlogix Corp's revenue or net income, to determine how well the company is positioned to perform in the future. Although Resverlogix Corp investors may analyze each financial statement separately, they are all interrelated. For example, changes in Resverlogix Corp's assets and liabilities are reflected in the revenues and expenses on Resverlogix Corp's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Resverlogix Corp. Please read more on our technical analysis and fundamental analysis pages.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. RESVERLOGIX CORP operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 22 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Resverlogix Pink Sheet
Resverlogix Corp financial ratios help investors to determine whether Resverlogix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Resverlogix with respect to the benefits of owning Resverlogix Corp security.